Fludeoxyglucose F 18

Highest phase reached
Approved
www.ebi.ac.uk
Drug type
Small molecule
www.ebi.ac.uk
First approval year
1994
www.ebi.ac.uk

First approval year
1994
www.ebi.ac.uk
Listing at source
Listed
Highest phase reached
Approved
www.ebi.ac.uk

Drug type
Small molecule
www.ebi.ac.uk
Drug name
Fludeoxyglucose F 18
www.ebi.ac.uk
Molecular weight
181.15
www.ebi.ac.uk
Structure (SMILES)
OC[C@H]1OC(O)[C@H]([18F])[C@@H](O)[C@@H]1O
www.ebi.ac.uk

  • fludeoxyglucose f18
  • Fludeoxyglucose f18

  • (18f)-fdg
  • (18f)-fluorodeoxyglucose
  • (18f)fdg
  • (18f)fluoro-2-deoxyglucose
  • (18f)fluorodeoxyglucose
  • [18-F] Fluorodeoxyglucose (FDG)
  • [18F]-FDG
  • [18F]-Fluorodeoxyglucose
  • [18F]FDG
  • [18F]fluoro-2-deoxy-D-glucose (FDG)
  • [18F]fluorodeoxyglucose
  • [18F]Fluorodeoxyglucose
  • 18 f fdg
  • 18 f fluorodeoxyglucose fdg
  • 18 fdg
  • 18-f fdg
  • 18-F FDG
  • 18-FDG
  • 18f
  • 18f fdg
  • 18f fluoro 2 deoxyglucose
  • 18f fluorodeoxyglucose
  • 18F- fluorodeoxyglucose
  • 18F-deoxyglucose (FDG)
  • 18f-fdg

And 53 more, listed on the interactive page.

ATC classification codes
  • V09IX04
Sources for recorded values
www.ebi.ac.uk
ChEMBL ID
CHEMBL2030434
www.ebi.ac.uk
InChIKey
ZCXUVYAZINUVJD-GLCXRVCCSA-N
www.ebi.ac.uk
PubChem compound IDs
  • 11469444
RxNorm IDs (RxCUI)
  • 1362737

Patents
0
Designations
1
First in class
No
Fast track
No
Breakthrough designation
No
Orphan designation
No
Priority review
Yes
Orphan exclusivity
No
Accelerated approval
No
Availability
Prescription only

Administration routes

  • Parenteral

  • Condition
    Carcinoma, Hepatocellular
    Highest recorded phase
    2
    Condition identifier
    EFO:0000182
    Subject identifier
    D006528
  • Condition
    Hodgkin Disease
    Highest recorded phase
    2
    Condition identifier
    EFO:0000183
    Subject identifier
    D006689
  • Condition
    Prostatic Neoplasms
    Highest recorded phase
    2
    Condition identifier
    EFO:0000196
    Subject identifier
    D011471
  • Condition
    Leukemia, Myeloid, Acute
    Highest recorded phase
    3
    Condition identifier
    EFO:0000222
    Subject identifier
    D015470
  • Condition
    Leukemia, Promyelocytic, Acute
    Highest recorded phase
    1
    Condition identifier
    EFO:0000224
    Subject identifier
    D015473
  • Condition
    Breast Neoplasms
    Highest recorded phase
    2
    Condition identifier
    EFO:0000305
    Subject identifier
    D001943
  • Condition
    Cardiovascular Diseases
    Highest recorded phase
    0.5
    Condition identifier
    EFO:0000319
    Subject identifier
    D002318
  • Condition
    Carcinoma, Renal Cell
    Highest recorded phase
    1
    Condition identifier
    EFO:0000349
    Subject identifier
    D002292
  • Condition
    Adenocarcinoma, Follicular
    Highest recorded phase
    2
    Condition identifier
    EFO:0000501
    Subject identifier
    D018263
  • Condition
    Stomach Neoplasms
    Highest recorded phase
    2
    Condition identifier
    EFO:0000503
    Subject identifier
    D013274
  • Condition
    Glioblastoma
    Highest recorded phase
    2
    Condition identifier
    EFO:0000519
    Subject identifier
    D005909
  • Condition
    Lymphoma
    Highest recorded phase
    3
    Condition identifier
    EFO:0000574
    Subject identifier
    D008223
  • Condition
    Mesothelioma
    Highest recorded phase
    1
    Condition identifier
    EFO:0000588
    Subject identifier
    D008654
  • Condition
    Neoplasms
    Highest recorded phase
    2
    Condition identifier
    EFO:0000616
    Subject identifier
    D009369
  • Condition
    Thyroid Neoplasms
    Highest recorded phase
    2
    Condition identifier
    EFO:0000641
    Subject identifier
    D013964
  • Condition
    Prostatic Neoplasms
    Highest recorded phase
    2
    Condition identifier
    EFO:0000673
    Subject identifier
    D011471
  • Condition
    Arthritis, Rheumatoid
    Highest recorded phase
    1
    Condition identifier
    EFO:0000685
    Subject identifier
    D001172
  • Condition
    Sarcoma
    Highest recorded phase
    2
    Condition identifier
    EFO:0000691
    Subject identifier
    D012509
  • Condition
    Melanoma
    Highest recorded phase
    1
    Condition identifier
    EFO:0000756
    Subject identifier
    D008545
  • Condition
    Idiopathic Pulmonary Fibrosis
    Highest recorded phase
    1
    Condition identifier
    EFO:0000768
    Subject identifier
    D054990
  • Condition
    Multiple Myeloma
    Highest recorded phase
    1
    Condition identifier
    EFO:0001378
    Subject identifier
    D009101
  • Condition
    Uterine Cervical Neoplasms
    Highest recorded phase
    2
    Condition identifier
    EFO:0001416
    Subject identifier
    D002583
  • Condition
    Hematologic Neoplasms
    Highest recorded phase
    1
    Condition identifier
    EFO:0001642
    Subject identifier
    D019337
  • Condition
    Prostatic Neoplasms
    Highest recorded phase
    2
    Condition identifier
    EFO:0001663
    Subject identifier
    D011471
  • Condition
    Pancreatic Neoplasms
    Highest recorded phase
    2
    Condition identifier
    EFO:0002618
    Subject identifier
    D010190

And 27 more, listed on the interactive page.

  • Condition identifier
    EFO_0000319
  • Condition identifier
    EFO_0000756
  • Condition identifier
    EFO_0001416
    Highest recorded phase
    1
  • Condition identifier
    EFO_0003060
  • Condition identifier
    HP_0001082
  • Condition identifier
    MONDO_0002367
    Highest recorded phase
    2
  • Condition identifier
    MONDO_0002974
  • Condition identifier
    MONDO_0004975
    Highest recorded phase
    1
  • Condition identifier
    MONDO_0005005
    Highest recorded phase
    2
  • Condition identifier
    MONDO_0005192
    Highest recorded phase
    2
  • Condition identifier
    MONDO_0005233
    Highest recorded phase
    2
  • Condition identifier
    MONDO_0006047
    Highest recorded phase
    2
  • Condition identifier
    MONDO_0007254
  • Condition identifier
    MONDO_0008667
    Highest recorded phase
    2
  • Condition identifier
    MONDO_0008903
  • Condition identifier
    MONDO_0016698
    Highest recorded phase
    2
  • Condition identifier
    MONDO_0018907
    Highest recorded phase
    2

  • Event
    bone lesion
    Reports
    2
    Reporting signal score
    9.3195
  • Event
    glioblastoma multiforme
    Reports
    2
    Reporting signal score
    12.8687
  • Event
    hyperproteinaemia
    Reports
    2
    Reporting signal score
    14.788
  • Event
    neuroendocrine tumour
    Reports
    2
    Reporting signal score
    11.8532
  • Event
    occupational exposure to radiation
    Reports
    2
    Reporting signal score
    19.7811
  • Event
    second primary malignancy
    Reports
    2
    Reporting signal score
    7.64211

And 43 more, listed on the interactive page.

Dose
5-10 mCi
Route
Intravenous
How often
As needed

  • Acquire images 30 to 100 minutes from injection
  • Initiate imaging within 40 minutes
  • Use within 12 hours from the EOS

Hydrogen bond acceptors
5
Hydrogen bond donors
4
Polar surface area
90.15
Calculated partition coefficient (ALogP)
-2.24
Calculated partition coefficient (XLogP)
-1.6
Prodrug
No
Chirality
Single enantiomer
Inorganic
No
Rule-of-five violations
0
Rotatable bonds
1
Heavy atoms
12
Molecular formula
C6H11FO5
Monoisotopic mass
181.061586
Natural product
No

Recorded assays
61
Active assays
0

Related records

Trials (576)

In development for (52)